ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
EyePoint Announces First Patient Dosed in Trial of EYP-1901 for Wet AMD americanpharmaceuticalreview
February 03, 2021EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD). -
EyePoint Reports Positive Results from GLP Toxicology Study of EYP-1901 americanpharmaceuticalreview
December 24, 2020EyePoint Pharmaceuticals announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert? ...
Pharma Sources Insight January 2025
